175 related articles for article (PubMed ID: 38186306)
1. CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
Zhong K; Luo W; Li N; Tan X; Li Y; Yin S; Huang Y; Fang L; Ma W; Cai Y; Yin Y
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38186306
[TBL] [Abstract][Full Text] [Related]
2. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.
Lei H; Wang Z; Jiang D; Liu F; Liu M; Lei X; Yang Y; He B; Yan M; Huang H; Liu Q; Pang J
Cell Death Dis; 2021 Jul; 12(8):740. PubMed ID: 34315855
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
Frei K; Schecher S; Daher T; Hörner N; Richter J; Hildebrand U; Schindeldecker M; Witzel HR; Tsaur I; Porubsky S; Gaida MM; Roth W; Tagscherer KE
Int J Cancer; 2024 Mar; 154(6):1082-1096. PubMed ID: 37916780
[TBL] [Abstract][Full Text] [Related]
4. CDK12 Promotes the Proliferation, Migration, and Angiogenesis of Gastric Carcinoma via Activating the PI3K/AKT/mTOR Signaling Pathway.
Gao LZ; Wang JQ; Chen JL; Zhang XL; Zhang MM; Wang SL; Zhao C
Appl Biochem Biotechnol; 2023 Nov; 195(11):6913-6926. PubMed ID: 36951936
[TBL] [Abstract][Full Text] [Related]
5. Stromal insulin-like growth factor binding protein 3 (IGFBP3) is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation.
Sampson N; Zenzmaier C; Heitz M; Hermann M; Plas E; Schäfer G; Klocker H; Berger P
Endocrinology; 2013 Aug; 154(8):2586-99. PubMed ID: 23720424
[TBL] [Abstract][Full Text] [Related]
6. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.
Kawabata R; Oie S; Takahashi M; Kanayama H; Oka T; Itoh K
Int J Oncol; 2011 Jun; 38(6):1489-500. PubMed ID: 21455575
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.
Lin ZY; Chen G; Zhang YQ; He HC; Liang YX; Ye JH; Liang YK; Mo RJ; Lu JM; Zhuo YJ; Zheng Y; Jiang FN; Han ZD; Wu SL; Zhong WD; Wu CL
Mol Cancer; 2017 Feb; 16(1):48. PubMed ID: 28241827
[TBL] [Abstract][Full Text] [Related]
10. Nimbolide inhibits 2D and 3D prostate cancer cells migration, affects microtubules and angiogenesis and suppresses B-RAF/p.ERK-mediated in vivo tumor growth.
Mahmoud N; Dawood M; Huang Q; Ng JPL; Ren F; Wong VKW; Efferth T
Phytomedicine; 2022 Jan; 94():153826. PubMed ID: 34775358
[TBL] [Abstract][Full Text] [Related]
11. Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men.
Park K; Kim JH; Jeon HG; Byun SS; Lee E
Urology; 2010 Jun; 75(6):1516.e1-7. PubMed ID: 20350746
[TBL] [Abstract][Full Text] [Related]
12. MiR-384 Inhibits Malignant Biological Behavior Such as Proliferation and Invasion of Osteosarcoma by Regulating IGFBP3.
Tan Y; Chen L; Li S; Hao H; Zhang D
Technol Cancer Res Treat; 2020; 19():1533033820909125. PubMed ID: 32129151
[TBL] [Abstract][Full Text] [Related]
13. Bone morphogenetic protein 2 promotes human trophoblast cell invasion and endothelial-like tube formation through ID1-mediated upregulation of IGF binding protein-3.
Zhao HJ; Klausen C; Zhu H; Chang HM; Li Y; Leung PCK
FASEB J; 2020 Feb; 34(2):3151-3164. PubMed ID: 31908038
[TBL] [Abstract][Full Text] [Related]
14. Evaluating serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 as markers in prostate cancer diagnosis.
Rainato G; Fabricio AS; Zancan M; Peloso L; Dittadi R; Barichello M; Fandella A; Scattoni V; Gion M
Int J Biol Markers; 2016 Jul; 31(3):e317-23. PubMed ID: 26954072
[TBL] [Abstract][Full Text] [Related]
15. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
[TBL] [Abstract][Full Text] [Related]
17. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
[TBL] [Abstract][Full Text] [Related]
18. IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer.
Mayo JC; Hevia D; Quiros-Gonzalez I; Rodriguez-Garcia A; Gonzalez-Menendez P; Cepas V; Gonzalez-Pola I; Sainz RM
J Pineal Res; 2017 Jan; 62(1):. PubMed ID: 27736013
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis.
Zhang W; Zhou L; Di J
Expert Rev Anticancer Ther; 2023 Feb; 23(2):207-216. PubMed ID: 36734254
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.
Schumacher FR; Cheng I; Freedman ML; Mucci L; Allen NE; Pollak MN; Hayes RB; Stram DO; Canzian F; Henderson BE; Hunter DJ; Virtamo J; Manjer J; Gaziano JM; Kolonel LN; Tjønneland A; Albanes D; Calle EE; Giovannucci E; Crawford ED; Haiman CA; Kraft P; Willett WC; Thun MJ; Le Marchand L; Kaaks R; Feigelson HS; Bueno-de-Mesquita HB; Palli D; Riboli E; Lund E; Amiano P; Andriole G; Dunning AM; Trichopoulos D; Stampfer MJ; Key TJ; Ma J
Hum Mol Genet; 2010 Aug; 19(15):3089-101. PubMed ID: 20484221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
